Clinical Research

Optic Coherence Tomography Findings in Hyperthyroid Patients without Ophthalmopathy

Volume: 13 Number: 1 January 20, 2023
TR EN

Optic Coherence Tomography Findings in Hyperthyroid Patients without Ophthalmopathy

Abstract

Aim The aim of this study is to compare the choroidal, retinal, and peripapillary nerve fiber layer thickness of the patients diagnosed with hyperthyroidism but did not develop ophthalmopathy with the euthyroid patients. Material and Methods: Thyroid stimulating hormone (TSH), freeT3 (fT3) and freeT4 (fT4) tests of the patients were analyzed. Cases who came in with symptoms of hyperthyroidism and had a TSH lower than 0.5 mu/L were included to the study. Retinal thickness (RT), retinal nerve fiber layer (RNFL) thickness, and choroidal thickness (CT) were calculated by means of spectral domain optical coherence tomography. Results: A total of 82 participants, covering 40 (49%) hyperthyroid patients and 42 (51%) euthyroid healthy individuals, were examined. In terms of RT measurements, T500,T1000,T1500 and N1500 values were found to be lower in the HT group compared to the control group, and they were statistically significant (p<0.001; p<0.001; p<0.001; p=0.011;respectively). In terms of CT measurements, Central, N500,N1000 and N1500,T500,T1000,T1500 values were found to be lower in the HT group and they were statistically significant (p=0.003; p=0.002; p=0.005; p=0.005; p=0.002; p=0.002; p=0.028; respectively). In terms of RNFL measurements, T, TS, TI segments were found to be lower and NI segment was found to be higher in the HT group compared to the control group, and this difference was statistically significant (p=0.008; p=0.001; p=0.002 and p=0.009; respectively). Conclusion: As a result, it is advised to regularly perform eye controls of patients with hyperthyroidism, not only the ones with ophthalmopathy but also those without ophthalmopathy, after the diagnosis.

Keywords

References

  1. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018; 14(5): 301-16.
  2. Mansourian AR. Metabolic pathways of tetraidothyronine and triidothyronine production by thyroid gland: a review of articles. Pak J Biol Sci. 2011; 14(1): 1-12.
  3. Liu ZW, Masterson L, Fish B, Jani P, Chatterjee K. Thyroid surgery for Graves’ disease and Graves’ ophthalmopathy. Cochrane Database Syst Rev. 2015; 25(11): 1-7.
  4. Schmidt M, Voell M, Rahlff I, Dietlein M, Kobe C, Faust M, et al. Long-term follow-up of antithyroid peroxidase antibodies in patients with chronic autoimmune thyroiditis (Hashimoto’s thyroiditis) treated with levothyroxine. Thyroid. 2008; 18: 755-60.
  5. Marino M, Ionni I, Lanzolla G, Sframeli A, Latrofa F, Rocchi R, et al. Orbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis. J Endocrinol Invest. 2020; 43: 401-11.
  6. Levy J, Puterman M, Lifshitz T, Marcus M, Segal A, Monos T. Endoscopic orbital decompression for Graves’ ophthalmopathy. Isr Med Assoc J. 2004; 6(11): 673-6.
  7. Casini G, Marino M, Rubino M, Licari S, Covello G, Mazzi B, et al. Retinal, choroidal and optic disc analysis in patients with Graves’ disease with or without orbitopathy. Int Ophthalmol. 2020; 40(9): 2129-37.
  8. Kurt MM, Akpolat C, Evliyaoglu F, Yilmaz M, Ordulu F. Evaluation of retinal neurodegeneration and choroidal thickness in patients with ınactive graves’ ophthalmopathy. Klin Monbl Augenheilkd. 2021; 238(7): 797-802.

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

Clinical Research

Publication Date

January 20, 2023

Submission Date

June 21, 2022

Acceptance Date

December 29, 2022

Published in Issue

Year 2023 Volume: 13 Number: 1

APA
Eski, M. T., Teberik, K., Sezer, T., & Önmez, A. (2023). Optic Coherence Tomography Findings in Hyperthyroid Patients without Ophthalmopathy. Value in Health Sciences, 13(1), 123-128. https://doi.org/10.33631/sabd.1133402
AMA
1.Eski MT, Teberik K, Sezer T, Önmez A. Optic Coherence Tomography Findings in Hyperthyroid Patients without Ophthalmopathy. VHS. 2023;13(1):123-128. doi:10.33631/sabd.1133402
Chicago
Eski, Mehmet Tahir, Kuddusi Teberik, Taha Sezer, and Atilla Önmez. 2023. “Optic Coherence Tomography Findings in Hyperthyroid Patients Without Ophthalmopathy”. Value in Health Sciences 13 (1): 123-28. https://doi.org/10.33631/sabd.1133402.
EndNote
Eski MT, Teberik K, Sezer T, Önmez A (January 1, 2023) Optic Coherence Tomography Findings in Hyperthyroid Patients without Ophthalmopathy. Value in Health Sciences 13 1 123–128.
IEEE
[1]M. T. Eski, K. Teberik, T. Sezer, and A. Önmez, “Optic Coherence Tomography Findings in Hyperthyroid Patients without Ophthalmopathy”, VHS, vol. 13, no. 1, pp. 123–128, Jan. 2023, doi: 10.33631/sabd.1133402.
ISNAD
Eski, Mehmet Tahir - Teberik, Kuddusi - Sezer, Taha - Önmez, Atilla. “Optic Coherence Tomography Findings in Hyperthyroid Patients Without Ophthalmopathy”. Value in Health Sciences 13/1 (January 1, 2023): 123-128. https://doi.org/10.33631/sabd.1133402.
JAMA
1.Eski MT, Teberik K, Sezer T, Önmez A. Optic Coherence Tomography Findings in Hyperthyroid Patients without Ophthalmopathy. VHS. 2023;13:123–128.
MLA
Eski, Mehmet Tahir, et al. “Optic Coherence Tomography Findings in Hyperthyroid Patients Without Ophthalmopathy”. Value in Health Sciences, vol. 13, no. 1, Jan. 2023, pp. 123-8, doi:10.33631/sabd.1133402.
Vancouver
1.Mehmet Tahir Eski, Kuddusi Teberik, Taha Sezer, Atilla Önmez. Optic Coherence Tomography Findings in Hyperthyroid Patients without Ophthalmopathy. VHS. 2023 Jan. 1;13(1):123-8. doi:10.33631/sabd.1133402